Merck KGaA - Company Profile
Powered by 
All the data and insights you need on Merck KGaA in one report.
$295
- Save hours of research time and resources with
our up-to-date Merck KGaA Strategy Report
- Understand Merck KGaA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreMerck KGaA (Merck), a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops, and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.
Headquarters
Germany
Address
Frankfurter Str. 250, Darmstadt, Hessen, 64293
Website
www.emdgroup.com
Telephone
49 6151 720
No of Employees
62,908
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MRK (ETR)
Revenue (2022)
$22.7B
-5.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-15.1%
(2022 vs 2021)
Market Cap*
$71.1B
Net Profit Margin (2022)
XYZ
-10.1%
(2022 vs 2021)
* As of and is in US$
Merck KGaA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Prescription Drugs | Single-use Manufacturing | Apaisyl |
| Liquid Crystal Mixtures | Sterile Filtration | Bion |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Corporate Changes/Expansions | In March, the company opened a new office in Riyadh, Saudi Arabia. |
| 2024 | Corporate Changes/Expansions | In March, the company invested more than EUR300 million in a new Bioprocessing Production Center in Daejeon, South Korea. |
| 2024 | Plans/Strategy | In February, the company announced its plans to launch a new distribution center in Cajamar, Sao Paulo, Brazil. |
Competitor Comparison
| Key Parameters | Merck KGaA | F. Hoffmann-La Roche Ltd | Bayer AG | Sanofi | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | Germany | Switzerland | Germany | France | Switzerland |
| City | Darmstadt | Basel | Leverkusen | Paris | Basel |
| State/Province | Hessen | - | Nordrhein-Westfalen | Ile-de-France | - |
| No. of Employees | 62,908 | 103,605 | 99,723 | 87,994 | 76,057 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Helene von Roeder | Director; Chief Financial Officer | Executive Board | 2023 | - |
| Belen Garijo | Chief Executive Officer | Senior Management | 2021 | - |
| Peter Guenter | Chief Executive Officer - Healthcare | Senior Management | 2021 | - |
| Matthias Heinzel | Chief Executive Officer - Life Science | Senior Management | 2021 | - |
| Kai Beckmann | Chief Executive Officer - Electronics business | Senior Management | 2017 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward